admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

PT339 – Kim Dudine – Cannabis: The Gateway Drug to Unity...

Psychedelic Investor Pulse Survey Results (Summer 2022)

PT338 – Melissa Lavasani – The Power of Storytelling, The Preservation...

George Tziras to Succeed Peter Rands as Small Pharma Chief...

Small Pharma Reports Fiscal First Quarter 2023 Highlights

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

Numinus Wellness Inc. Reports Q3 2022 Results

1...133134135...218 Page 134 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

PT339 – Kim Dudine – Cannabis: The Gateway Drug to Unity...

Psychedelic Investor Pulse Survey Results (Summer 2022)

PT338 – Melissa Lavasani – The Power of Storytelling, The Preservation...

George Tziras to Succeed Peter Rands as Small Pharma Chief...

Small Pharma Reports Fiscal First Quarter 2023 Highlights

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT

Numinus Wellness Inc. Reports Q3 2022 Results

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY